Go Pro

This company recently went public with an IPO on Wednesday, August 5th 2026. They issued 17,000,000 shares at $15.00 - $17.00 per share. We will continue to update data for ATTO as it becomes available.

NASDAQ:ATTO

Attovia Therapeutics (ATTO) Stock Price, News & Analysis

$20.17 -0.21 (-1.03%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$20.22 +0.05 (+0.25%)
As of 08/7/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Attovia Therapeutics Stock (NASDAQ:ATTO)

Advanced

Key Stats

Today's Range
$18.64
$20.94
50-Day Range
N/A
52-Week Range
$18.64
$22.79
Volume
237,906 shs
Average Volume
325,553 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Attovia Therapeutics, Inc. (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways. Its pipeline is centered on potential treatments for conditions involving dysregulated immune responses, although many of its programs remain in development and are subject to clinical and regulatory evaluation.

As a development-stage biotechnology company, Attovia’s activities primarily involve research, preclinical studies, clinical trials and the advancement of its proprietary therapeutic pipeline. Publicly available information provides limited detail about its commercial operations, geographic reach and leadership beyond its focus on developing innovative treatments for inflammatory diseases.

AI Generated. May Contain Errors.

Receive ATTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Attovia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ATTO Stock News Headlines

See More Headlines

ATTO Stock Analysis - Frequently Asked Questions

Attovia Therapeutics' stock was trading at $21.90 on August 5, 2026. Since then, ATTO shares have decreased by 7.9% and is now trading at $20.17.

Attovia Therapeutics (ATTO) raised $272 million in an initial public offering (IPO) on Wednesday, August 5th 2026. The company issued 17,000,000 shares at a price of $15.00-$17.00 per share.

Attovia Therapeutics's quiet period expires on Monday, September 14th. Attovia Therapeutics had issued 17,000,000 shares in its initial public offering on August 5th. The total size of the offering was $289,000,000 based on an initial share price of $17.00. During the company's quiet period, insiders and any underwriters involved in the IPO are restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Attovia Therapeutics' top institutional shareholders include BlackRock Inc.. Insiders that own company stock include Life Sciences Xi LP Frazier and Redmile Group, Llc.
View institutional ownership trends
.

Shares of ATTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:ATTO
CIK
2058707
Web
N/A
Fax
N/A
Employees
44
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
N/A
Beta
N/A
10 Best Stocks to Own - Summer 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:ATTO) was last updated on 8/8/2026 by MarketBeat.com Staff.
From Our Partners